secwatch.observer — SEC 8-K summary
======================================

Issuer:     CapsoVision, Inc (CV)
CIK:        0001378325
Form:       8-K
Filed at:   2026-09-28T15:03:33+00:00
Accession:  0001378325-26-000045
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

CapsoVision wins FDA clearance for AI Highlights, its AI-assisted reading tool for CapsoCam Plus
--------------------------------------------------------------------------------

- FDA cleared AI Highlights on September 25, 2026; CapsoVision announced the clearance on September 28, 2026.
- Tool marks suspected abnormal lesions in small bowel capsule endoscopy studies for adults and pediatric patients over age two with suspected small bowel bleeding.
- Aims to cut physician review time; integrates with CapsoView review software and CapsoCloud workflows without a separate AI platform.
- AI Highlights launched internationally earlier in 2026, including the EU under Medical Device Regulation, per CEO Johnny Wang.
- Company notes the tool is not intended to replace gastroenterologists' diagnostic interpretation or histopathological sampling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1378325/000137832526000045/0001378325-26-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1378325/000137832526000045/cv-20260925.htm
  HTML page:      https://secwatch.observer/filing/0001378325-26-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer